Jonathan D Powell

List of Publications by Year
in descending order

#	Article	IF	Citations
1	The mTOR Kinase Differentially Regulates Effector and Regulatory T Cell Lineage Commitment. Immunity, 2009, 30, 832-844.	14.3	1,079
2	Role of LAG-3 in Regulatory T Cells. Immunity, 2004, 21, 503-513.	14.3	1,040
3	The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nature Immunology, 2011, 12, 295-303.	14.5	970
4	Regulation of Immune Responses by mTOR. Annual Review of Immunology, 2012, 30, 39-68.	21.8	689
5	Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science, 2019, 366, 1013-1021.	12.6	643
6	Developing a pro-regenerative biomaterial scaffold microenvironment requires T helper 2 cells. Science, 2016, 352, 366-370.	12.6	464
7	A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood, 2008, 111, 251-259.	1.4	431
8	The Mammalian Target of Rapamycin: Linking T Cell Differentiation, Function, and Metabolism. Immunity, 2010, 33, 301-311.	14.3	429
9	Metabolism of immune cells in cancer. Nature Reviews Cancer, 2020, 20, 516-531.	28.4	407
10	Egr-2 and Egr-3 are negative regulators of T cell activation. Nature Immunology, 2005, 6, 472-480.	14.5	382
11	Allogeneic Hematopoietic Stem-Cell Transplantation for Sickle Cell Disease. New England Journal of Medicine, 2009, 361, 2309-2317.	27.0	381
12	<scp>mTOR</scp>, metabolism, and the regulation of Tâ€cell differentiation and function. Immunological Reviews, 2012, 249, 43-58.	6.0	335
13	mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation. Journal of Clinical Investigation, 2015, 125, 2090-2108.	8.2	329
14	Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. Nature Reviews Immunology, 2014, 14, 435-446.	22.7	323
15	A Role for Mammalian Target of Rapamycin in Regulating T Cell Activation versus Anergy. Journal of Immunology, 2007, 178, 2163-2170.	0.8	252
16	Anergic T Cells Are Metabolically Anergic. Journal of Immunology, 2009, 183, 6095-6101.	0.8	243
17	Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. Journal of Clinical Investigation, 2020, 130, 3865-3884.	8.2	230
18	Estrogen-related receptor-Î± is a metabolic regulator of effector T-cell activation and differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18348-18353.	7.1	200

#	Article	IF	Citations
19	Asymmetric inheritance of mTORC1 kinase activity during division dictates CD8+ T cell differentiation. Nature Immunology, 2016, 17, 704-711.	14.5	199
20	A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. Computational and Structural Biotechnology Journal, 2015, 13, 265-272.	4.1	188
21	Molecular regulation of interleukinâ€2 expression by CD28 coâ€stimulation and anergy. Immunological Reviews, 1998, 165, 287-300.	6.0	176
22	Targeting metabolism to regulate immune responses in autoimmunity and cancer. Nature Reviews Drug Discovery, 2019, 18, 669-688.	46.4	176
23	Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR. Cell, 2018, 174, 72-87.e32.	28.9	172
24	The Receptor SIGIRR Suppresses Th17 Cell Proliferation via Inhibition of the Interleukin-1 Receptor Pathway and mTOR Kinase Activation. Immunity, 2010, 32, 54-66.	14.3	171
25	The PTEN pathway in T _{regs} is a critical driver of the suppressive tumor microenvironment. Science Advances, 2015, 1, e1500845.	10.3	167
26	Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood, 2014, 124, 3817-3827.	1.4	165
27	The AGC kinase SGK1 regulates TH1 and TH2 differentiation downstream of the mTORC2 complex. Nature Immunology, 2014, 15, 457-464.	14.5	163
28	Regulation of T cells by mTOR: the known knowns and the known unknowns. Trends in Immunology, 2015, 36, 13-20.	6.8	163
29	Preventing Allograft Rejection by Targeting Immune Metabolism. Cell Reports, 2015, 13, 760-770.	6.4	156
30	The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. Journal of Experimental Medicine, 2017, 214, 381-400.	8.5	154
31	A Central Role for mTOR Kinase in Homeostatic Proliferation Induced CD8+ T Cell Memory and Tumor Immunity. Immunity, 2011, 34, 541-553.	14.3	142
32	Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunology, Immunotherapy, 2012, 61, 917-926.	4.2	134
33	Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models. Cancer Immunology, Immunotherapy, 2018, 67, 1271-1284.	4.2	131
34	Immune dysregulation as a driver of idiopathic pulmonary fibrosis. Journal of Clinical Investigation, 2021, 131, .	8.2	114
35	Threat Matrix: Low-Molecular-Weight Hyaluronan (HA) as a Danger Signal. Immunologic Research, 2005, 31, 207-218.	2.9	112
36	De novo DNA methylation by DNA methyltransferase 3a controls early effector CD8 ⁺ T-cell fate decisions following activation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10631-10636.	7.1	107

#	Article	IF	Citations
37	Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Science Translational Medicine, 2015, 7, 288ra78.	12.4	104
38	mTOR: taking cues from the immune microenvironment. Immunology, 2009, 127, 459-465.	4.4	100
39	mTOR Complex 1 Signaling Regulates the Generation and Function of Central and Effector Foxp3+ Regulatory T Cells. Journal of Immunology, 2018, 201, 481-492.	0.8	100
40	Leucine Metabolism in T Cell Activation: mTOR Signaling and Beyond. Advances in Nutrition, 2016, 7, 798S-805S.	6.4	99
41	Discovery of 6-Diazo-5-oxo-<scp>l</scp>-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma. Journal of Medicinal Chemistry, 2016, 59, 8621-8633.	6.4	98
42	PKG1-modified TSC2 regulates mTORC1 activity to counter adverse cardiac stress. Nature, 2019, 566, 264-269.	27.8	98
43	Opposing regulation of T cell function by Egrâ€1/NAB2 and Egrâ€2/Egrâ€3. European Journal of Immunology, 2008, 38, 528-536.	2.9	96
44	An engineered IL-2 partial agonist promotes CD8+ T cell stemness. Nature, 2021, 597, 544-548.	27.8	94
45	Identification of DNA Methyltransferase 3a as a T Cell Receptor-Induced Regulator of Th1 and Th2 Differentiation. Journal of Immunology, 2009, 183, 2267-2276.	0.8	93
46	Metabolic programs define dysfunctional immune responses in severe COVID-19 patients. Cell Reports, 2021, 34, 108863.	6.4	92
47	Targeting T cell metabolism to regulate T cell activation, differentiation and function in disease. Current Opinion in Immunology, 2017, 46, 82-88.	5.5	88
48	Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT. Blood Advances, 2017, 1, 652-661.	5.2	84
49	Targeting Metabolism as a Novel Therapeutic Approach to Autoimmunity, Inflammation, and Transplantation. Journal of Immunology, 2017, 198, 999-1005.	0.8	82
50	Cytosolic Branched Chain Aminotransferase (BCATc) Regulates mTORC1 Signaling and Glycolytic Metabolism in CD4+ T Cells. Journal of Biological Chemistry, 2014, 289, 18793-18804.	3.4	73
51	Natural and inducible TH17 cells are regulated differently by Akt and mTOR pathways. Nature Immunology, 2013, 14, 611-618.	14.5	72
52	Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses. Journal of Clinical Investigation, 2021, 131, .	8.2	72
53	Targeting glutamine metabolism rescues mice from late-stage cerebral malaria. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13075-13080.	7.1	66
54	Feeding an army: The metabolism of T cells in activation, anergy, and exhaustion. Molecular Immunology, 2015, 68, 492-496.	2.2	65

#	ARTICLE	IF	CITATIONS
55	Mammalian Target of Rapamycin Integrates Diverse Inputs To Guide the Outcome of Antigen Recognition in T Cells. Journal of Immunology, 2012, 188, 4721-4729.	0.8	59
56	Cutting Edge: TCR-Induced NAB2 Enhances T Cell Function by Coactivating IL-2 Transcription. Journal of Immunology, 2006, 177, 8301-8305.	0.8	55
57	The induction and maintenance of T cell anergy. Clinical Immunology, 2006, 120, 239-246.	3.2	51
58	Hyaluronan Fragments Promote Inflammation by Down-Regulating the Anti-inflammatory A2a Receptor. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 675-683.	2.9	50
59	The Adenosine A2a Receptor Inhibits Matrix-Induced Inflammation in a Novel Fashion. American Journal of Respiratory Cell and Molecular Biology, 2009, 40, 251-259.	2.9	49
60	The Novel Cyclophilin Binding Compound, Sanglifehrin A, Disassociates G1 Cell Cycle Arrest from Tolerance Induction. Journal of Immunology, 2004, 172, 4797-4803.	0.8	46
61	Mammalian Target of Rapamycin Complex 2 Regulates Invariant NKT Cell Development and Function Independent of Promyelocytic Leukemia Zinc-Finger. Journal of Immunology, 2015, 194, 223-230.	0.8	46
62	mTORC2 Signaling Selectively Regulates the Generation and Function of Tissue-Resident Peritoneal Macrophages. Cell Reports, 2017, 20, 2439-2454.	6.4	45
63	NF-Î°B Activation Mediates the Cross-talk between Extracellular Matrix and Interferon-Î³ (IFN-Î³) Leading to Enhanced Monokine Induced by IFN-Î³ (MIG) Expression in Macrophages. Journal of Biological Chemistry, 2002, 277, 43757-43762.	3.4	43
64	Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning. Blood, 2022, 139, 608-623.	1.4	42
65	Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice. Communications Biology, 2022, 5, 242.	4.4	42
66	Cellular Size as a Means of Tracking mTOR Activity and Cell Fate of CD4+ T Cells upon Antigen Recognition. PLoS ONE, 2015, 10, e0121710.	2.5	39
67	mTORC1 Promotes T-bet Phosphorylation To Regulate Th1 Differentiation. Journal of Immunology, 2017, 198, 3939-3948.	0.8	39
68	Rapamycin Inhibits Human Laryngotracheal Stenosisâ€"derived Fibroblast Proliferation, Metabolism, and Function in Vitro. Otolaryngology - Head and Neck Surgery, 2015, 152, 881-888.	1.9	37
69	Inhibition of the Adenosine Pathway to Potentiate Cancer Immunotherapy: Potential for Combinatorial Approaches. Annual Review of Medicine, 2021, 72, 331-348.	12.2	37
70	Dysregulated Macrophages Are Present in Bleomycinâ€Induced Murine Laryngotracheal Stenosis. Otolaryngology - Head and Neck Surgery, 2015, 153, 244-250.	1.9	35
71	Low-Dose Radiation Plus Rapamycin Promotes Long-Term Bone Marrow Chimerism. Transplantation, 2005, 80, 1541-1545.	1.0	33
72	Something in the Air: Hyperoxic Conditioning of the Tumor Microenvironment for Enhanced Immunotherapy. Cancer Cell, 2015, 27, 435-436.	16.8	32

#	Article	IF	Citations
73	Enhanced interaction between Hsp90 and raptor regulates mTOR signaling upon T cell activation. Molecular Immunology, 2009, 46, 2694-2698.	2.2	30
74	mTORC1 Signaling Regulates Proinflammatory Macrophage Function and Metabolism. Journal of Immunology, 2021, 207, 913-922.	0.8	27
75	Insight into the role of mTOR and metabolism in T cells reveals new potential approaches to preventing graft rejection. Current Opinion in Organ Transplantation, 2014, 19, 363-371.	1.6	26
76	MRI demonstrates glutamine antagonist-mediated reversal of cerebral malaria pathology in mice. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E12024-E12033.	7.1	26
77	Adenosine and anergy. Autoimmunity, 2007, 40, 425-432.	2.6	25
78	Macrophage A2A Adenosinergic Receptor Modulates Oxygen-Induced Augmentation of Murine Lung Injury. American Journal of Respiratory Cell and Molecular Biology, 2013, 48, 635-646.	2.9	24
79	A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas. Clinical Sarcoma Research, 2018, 8, 21.	2.3	22
80	Vaccinia vaccineâ€“based immunotherapy arrests and reverses established pulmonary fibrosis. JCI Insight, 2016, 1, e83116.	5.0	22
81	Non-parametric, hypothesis-based analysis of microarrays for comparison of several phenotypes. Bioinformatics, 2004, 20, 364-373.	4.1	21
82	Murine Full-thickness Skin Transplantation. Journal of Visualized Experiments, 2017, , .	0.3	21
83	A Modified Model of T-Cell Differentiation Based on mTOR Activity and Metabolism. Cold Spring Harbor Symposia on Quantitative Biology, 2013, 78, 125-130.	1.1	20
84	Dissecting the mechanism of T-cell anergy with immunophilin ligands. Current Opinion in Investigational Drugs, 2006, 7, 1002-7.	2.3	20
85	Sugar, fat, and protein: new insights into what T cells crave. Current Opinion in Immunology, 2015, 33, 49-54.	5.5	19
86	Distinct Requirements for C-C Chemokine and IL-2 Production by Naive, Previously Activated, and Anergic T Cells. Journal of Immunology, 2000, 164, 3996-4002.	0.8	18
87	Sensing the immune microenvironment to coordinate T cell metabolism, differentiation & function. Seminars in Immunology, 2012, 24, 414-420.	5.6	17
88	A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS). BMC Cancer, 2020, 20, 492.	2.6	16
89	Fueling the Revolution: Targeting Metabolism to Enhance Immunotherapy. Cancer Immunology Research, 2021, 9, 255-260.	3.4	16
90	Regulation of CD4+ and CD8+ Effector Responses by Sprouty-1. PLoS ONE, 2012, 7, e49801.	2.5	16

#	Article	IF	Citations
91	Identification of the Molecular Mechanism by which TLR Ligation and IFN-Î³ Synergize to Induce Mig. Clinical and Developmental Immunology, 2004, 11, 77-85.	3.3	13
92	Egr3 Induces a Th17 Response by Promoting the Development of Î³Î´ T Cells. PLoS ONE, 2014, 9, e87265.	2.5	13
93	Inhibition of glutamine metabolism accelerates resolution of acute lung injury. Physiological Reports, 2019, 7, e14019.	1.7	12
94	Fueling Memories. Immunity, 2012, 36, 3-5.	14.3	10
95	Warburg meets epigenetics. Science, 2016, 354, 419-420.	12.6	10
96	Hunger Pains: Stimulating the Appetite of the Immune System for Cancer. Cancer Cell, 2016, 30, 13-15.	16.8	8
97	Rethinking the adenosine-A2AR checkpoint: implications for enhancing anti-tumor immunotherapy. Current Opinion in Pharmacology, 2020, 53, 77-83.	3.5	7
98	Manipulation of Metabolic Pathways and Its Consequences for Anti-Tumor Immunity: A Clinical Perspective. International Journal of Molecular Sciences, 2020, 21, 4030.	4.1	7
99	An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncotarget, 2020, 11, 1929-1941.	1.8	7
100	Persistent CAD activity in memory CD8 ⁺ T cells supports rRNA synthesis and ribosomal biogenesis required at rechallenge. Science Immunology, 2022, 7, .	11.9	7
101	Genetic and biochemical regulation of CD4 T cell effector differentiation: insights from examination of T cell clonal anergy. Immunologic Research, 2010, 47, 162-171.	2.9	5
102	Slc7a5 helps T cells get with the program. Nature Immunology, 2013, 14, 422-424.	14.5	5
103	Deletion of mTORC1 Activity in CD4+ T Cells Is Associated with Lung Fibrosis and Increased Î³Î´ T Cells. PLoS ONE, 2016, 11, e0163288.	2.5	5
104	Targeting Metabolism as a Platform for Inducing Allograft Tolerance in the Absence of Long-Term Immunosuppression. Frontiers in Immunology, 2020, 11, 572.	4.8	5
105	Peeking under the Hood of Naive T Cells. Cell Metabolism, 2018, 28, 801-802.	16.2	4
106	Abstract 2337: The adenosine A2A receptor antagonist CPI-444 blocks adenosine-mediated T-cell suppression and exhibits antitumor activity alone and in combination with anti-PD-1 and anti-PD-L1. Cancer Research, 2016, 76, 2337-2337.	0.9	2
107	Interrogation of T Cellâ€“enriched Tumors Reveals Prognostic and Immunotherapeutic Implications of Polyamine Metabolism. Cancer Research Communications, 2022, 2, 639-652.	1.7	2
108	An Fcâ€“Small Molecule Conjugate for Targeted Inhibition of the Adenosineâ€…2A Receptor. ChemBioChem, 2016, 17, 1951-1960.	2.6	1

#	Article	IF	Citations
109	A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas.. Journal of Clinical Oncology, 2015, 33, 10560-10560.	1.6	1
110	Phase I/II Study of Marrow Infiltrating Lymphocytes (MILs) Generates Measurable Myeloma-Specific Immunity in the Autologous Stem Cell Transplant (SCT) Setting. Blood, 2011, 118, 997-997.	1.4	1
111	A phase II randomized trial of RAdium-223 dichloride and SABR versus SABR for oligomEtastatic prostate caNcerS (RAVENS).. Journal of Clinical Oncology, 2020, 38, TPS5586-TPS5586.	1.6	1
112	Bringing IL-2 down to earth. Blood, 2007, 109, 2671-2672.	1.4	0
113	Targeted immunosuppression: No longer naÃ¯ve. Clinical Immunology, 2012, 142, 95-96.	3.2	0
114	Cellular Metabolism Controls Lymphocyte Activation and Differentiation. , 2016, , 38-43.		0
115	A Novel Allogeneic Transplant Conditioning Regimen Designed for Tolerance Induction in Patients with Severe Sickle Cell Disease.. Blood, 2005, 106, 5429-5429.	1.4	0
116	A Novel Allogeneic Transplant Conditioning Regimen Designed for Tolerance Induction in Patients with Severe Sickle Cell Disease.. Blood, 2006, 108, 2994-2994.	1.4	0
117	Leucine metabolism as a novel approach to improve T cell performance in managing cancer. FASEB Journal, 2011, 25, 915.2.	0.5	0
118	The cytosolic branchedâ€chain aminotransferase (BCATc) regulates T cell activation via mTOR signaling pathway. FASEB Journal, 2012, 26, 127.6.	0.5	0
119	Akt and mTOR Pathways Differentially Regulate the Development of Natural and Inducible IL-17-Producing CD4+ T Cells. Blood, 2012, 120, 838-838.	1.4	0